Boston (1)

Recurrent Chronic Lymphoid Leukemia (1)

Active, not recruiting (1)

phase 1 (1)

Dana-Farber Cancer Institute (1)

Acetylon Pharmaceuticals Incorporated (1)

acy-1215 (1)

ibrutinib (1)

idelalisib (1)

drug (1)

Other (1)

Interventional (1)

recurrent chronic lymphoid leukemia

Showing 1 - 1 of 1

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

Active, not recruiting

Dec 19, 2022